Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis

被引:46
作者
Bellan, Steven E. [1 ]
Pulliam, Juliet R. C. [3 ,4 ]
Pearson, Carl A. B. [4 ]
Champredon, David [5 ]
Fox, Spencer J. [2 ]
Skrip, Laura [7 ]
Galvani, Alison P. [7 ,8 ]
Gambhir, Manoj [9 ,10 ,12 ]
Lopman, Ben A. [11 ,13 ]
Porco, Travis C. [14 ,15 ,16 ]
Meyers, Lauren Ancel [2 ,17 ]
Dushoff, Jonathan [6 ]
机构
[1] Univ Texas Austin, Ctr Computat Biol & Bioinformat, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Integrat Biol, Austin, TX 78712 USA
[3] Univ Florida, Dept Biol, Gainesville, FL USA
[4] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA
[5] McMaster Univ, Sch Computat Sci & Engn, Hamilton, ON, Canada
[6] McMaster Univ, Dept Biol, Hamilton, ON, Canada
[7] Yale Univ, Sch Publ Hlth, Ctr Infect Dis Modeling & Anal, New Haven, CT USA
[8] Yale Univ, Dept Ecol & Evolut, New Haven, CT USA
[9] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
[10] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA
[11] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA
[12] IHRC Inc, Atlanta, GA USA
[13] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[14] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA
[15] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA
[16] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[17] Santa Fe Inst, Santa Fe, NM 87501 USA
基金
美国国家卫生研究院; 加拿大健康研究院; 美国国家科学基金会;
关键词
STEPPED WEDGE CLUSTER; VIRUS DISEASE; SAMPLE-SIZE;
D O I
10.1016/S1473-3099(15)70139-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Safe and effective vaccines could help to end the ongoing Ebola virus disease epidemic in parts of west Africa, and mitigate future outbreaks of the virus. We assess the statistical validity and power of randomised controlled trial (RCT) and stepped-wedge cluster trial (SWCT) designs in Sierra Leone, where the incidence of Ebola virus disease is spatiotemporally heterogeneous, and is decreasing rapidly. Methods We projected district-level Ebola virus disease incidence for the next 6 months, using a stochastic model fitted to data from Sierra Leone. We then simulated RCT and SWCT designs in trial populations comprising geographically distinct clusters at high risk, taking into account realistic logistical constraints, and both individual-level and cluster-level variations in risk. We assessed false-positive rates and power for parametric and non-parametric analyses of simulated trial data, across a range of vaccine efficacies and trial start dates. Findings For an SWCT, regional variation in Ebola virus disease incidence trends produced increased false-positive rates (up to 0.15 at alpha=0.05) under standard statistical models, but not when analysed by a permutation test, whereas analyses of RCTs remained statistically valid under all models. With the assumption of a 6-month trial starting on Feb 18, 2015, we estimate the power to detect a 90% effective vaccine to be between 49% and 89% for an RCT, and between 6% and 26% for an SWCT, depending on the Ebola virus disease incidence within the trial population. We estimate that a 1-month delay in trial initiation will reduce the power of the RCT by 20% and that of the SWCT by 49%. Interpretation Spatiotemporal variation in infection risk undermines the statistical power of the SWCT. This variation also undercuts the SWCT's expected ethical advantages over the RCT, because an RCT, but not an SWCT, can prioritise vaccination of high-risk clusters.
引用
收藏
页码:703 / 710
页数:8
相关论文
共 22 条
[1]   Randomised controlled trials for Ebola: practical and ethical issues [J].
Adebamowo, Clement ;
Bah-Sow, Oumou ;
Binka, Fred ;
Bruzzone, Roberto ;
Caplan, Arthur ;
Delfraissy, Jean-Francois ;
Heymann, David ;
Horby, Peter ;
Kaleebu, Pontiano ;
Tamfum, Jean-Jacques Muyembe ;
Olliaro, Piero ;
Piot, Peter ;
Tejan-Cole, Abdul ;
Tomori, Oyewale ;
Toure, Aissatou ;
Torreele, Els ;
Whitehead, John .
LANCET, 2014, 384 (9952) :1423-1424
[2]  
[Anonymous], 2015, SUBN TIM SER DAT EB
[3]   EBOLA Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net [J].
Bellan, Steve E. ;
Pulliam, Juliet R. C. ;
Dushoff, Jonathan ;
Meyers, Lauren Ancel .
BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[4]  
Brown CA., 2006, BMC MED RES METHODOL, V6, P54, DOI [DOI 10.1186/1471-2288-6-54, 10.1186/1471-2288-6-54]
[5]  
Centers for Disease Control and Prevention, STRIVE SIERR LEON TR
[6]   Ebola vaccine trials raise ethical issues [J].
Cohen, Jon ;
Kupferschmidt, Kai .
SCIENCE, 2014, 346 (6207) :289-290
[7]   RANDOMIZATION BY GROUP - FORMAL ANALYSIS [J].
CORNFIELD, J .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1978, 108 (02) :100-102
[8]  
Davies MM., 2014, U.C. Berkeley Division of Biostatistics Working Paper Series
[9]   High hopes for Guinean vaccine trial [J].
Enserink, Martin .
SCIENCE, 2015, 347 (6219) :219-220
[10]   Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study [J].
Faye, Ousmane ;
Boelle, Pierre-Yves ;
Heleze, Emmanuel ;
Faye, Oumar ;
Loucoubar, Cheikh ;
Magassouba, N'Faly ;
Soropogui, Barre ;
Keita, Sakoba ;
Gakou, Tata ;
Bah, El Hadji Ibrahima ;
Koivogui, Lamine ;
Sall, Amadou Alpha ;
Cauchemez, Simon .
LANCET INFECTIOUS DISEASES, 2015, 15 (03) :320-326